PMV Pharmaceuticals Stock Forecast, Price & News

-0.30 (-0.92 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $32.37
50-Day Range
MA: $35.87
52-Week Range
Now: $32.37
Volume73,879 shs
Average Volume157,386 shs
Market Capitalization$1.45 billion
P/E RatioN/A
Dividend YieldN/A
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMV Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PMVP
Phone609 642 6670
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.45 billion
Next Earnings Date6/2/2021 (Estimated)
OptionableNot Optionable


PMV Pharmaceuticals (NASDAQ:PMVP) Sees Large Volume Increase
April 15, 2021 |
PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Down to $33.30
April 12, 2021 |
PMV Pharma Presents Late-Breaking Preclinical...
April 10, 2021 |
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 2.8%
April 9, 2021 |
PMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading Volume
April 5, 2021 |
Is PMVP A Good Stock To Buy Now?
December 16, 2020 |
PMV Pharmaceuticals Inc.
November 1, 2020 |
See More Headlines


Overall MarketRank

1.39 out of 5 stars

Medical Sector

672nd out of 2,025 stocks

Pharmaceutical Preparations Industry

324th out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.30 (-0.92 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PMVP News and Ratings via Email

Sign-up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PMV Pharmaceuticals (NASDAQ:PMVP) Frequently Asked Questions

Is PMV Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PMV Pharmaceuticals stock.
View analyst ratings for PMV Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than PMV Pharmaceuticals?

Wall Street analysts have given PMV Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PMV Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PMV Pharmaceuticals?

PMV Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,800,000 shares, an increase of 54.7% from the March 15th total of 1,810,000 shares. Based on an average daily volume of 155,600 shares, the days-to-cover ratio is presently 18.0 days. Currently, 8.8% of the company's shares are sold short.
View PMV Pharmaceuticals' Short Interest

When is PMV Pharmaceuticals' next earnings date?

PMV Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, June 2nd 2021.
View our earnings forecast for PMV Pharmaceuticals

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its quarterly earnings results on Wednesday, March, 3rd. The company reported $3.53 earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $4.80.
View PMV Pharmaceuticals' earnings history

What price target have analysts set for PMVP?

4 Wall Street analysts have issued 12 month price objectives for PMV Pharmaceuticals' stock. Their forecasts range from $34.00 to $42.00. On average, they anticipate PMV Pharmaceuticals' stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for PMV Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are PMV Pharmaceuticals' key executives?

PMV Pharmaceuticals' management team includes the following people:
  • Dr. David H. Mack, Co-Founder, CEO, Pres & Director (Age 59, Pay $628.11k)
  • Dr. Arnold J. Levine Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 81, Pay $100k)
  • Mr. Winston Kung, COO & CFO (Age 45, Pay $562.44k)
  • Dr. Deepika Jalota Pharm.D., Sr. VP of Regulatory Affairs & Quality Assurance (Age 45, Pay $388.25k)
  • Dr. Thomas E. Shenk Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 74)
  • Mr. Robert Ticktin, Gen. Counsel (Age 59)
  • Dr. Leila Alland, Chief Medical Officer (Age 59)

Who are some of PMV Pharmaceuticals' key competitors?

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).

When did PMV Pharmaceuticals IPO?

(PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is PMV Pharmaceuticals' stock symbol?

PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP."

When did PMV Pharmaceuticals' lock-up period expire?

PMV Pharmaceuticals' lock-up period expired on Wednesday, March 24th. PMV Pharmaceuticals had issued 11,765,000 shares in its initial public offering on September 25th. The total size of the offering was $211,770,000 based on an initial share price of $18.00. Since the end of PMV Pharmaceuticals' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Interwest Venture Management Co. (12.21%). Company insiders that own PMV Pharmaceuticals stock include Leila Alland, Ra Capital Management, LP and Thilo Schroeder.
View institutional ownership trends for PMV Pharmaceuticals

Which major investors are selling PMV Pharmaceuticals stock?

PMVP stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co.. Company insiders that have sold PMV Pharmaceuticals company stock in the last year include Leila Alland, and Thilo Schroeder.
View insider buying and selling activity for PMV Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PMV Pharmaceuticals' stock price today?

One share of PMVP stock can currently be purchased for approximately $32.37.

How much money does PMV Pharmaceuticals make?

PMV Pharmaceuticals has a market capitalization of $1.45 billion.

How many employees does PMV Pharmaceuticals have?

PMV Pharmaceuticals employs 44 workers across the globe.

What is PMV Pharmaceuticals' official website?

The official website for PMV Pharmaceuticals is

How can I contact PMV Pharmaceuticals?

The company can be reached via phone at 609 642 6670 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.